Events

2015 News Releases



Webcast ImageWebcast
Q1 2017 Rigel Pharmaceuticals Inc. Earnings Conference Call  (Live)
May 2, 2017 at 2:00 p.m. PT
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
11/03/15Rigel Announces Third Quarter 2015 Financial Results
- Conference Call and Webcast Today at 5:00 PM Eastern Time - SOUTH SAN FRANCISCO, Calif., Nov. 3, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, 2015. "We are concentrating our efforts on the timely completion of our two Phase 3 studies with fostamatinib in immune thrombocytopenic purpura (ITP). We expect topline data from the first Phase 3 trial in the middle of 2016 with the seco... 
 Printer Friendly Version
10/27/15Rigel Announces Conference Call and Webcast to Report Third Quarter 2015 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2015 financial results after market close on Tuesday, November 3, 2015.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results. Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-29... 
 Printer Friendly Version
09/09/15Rigel and Aclaris Therapeutics International Sign License Agreement for JAK Inhibitors to Treat Skin Disorders
SOUTH SAN FRANCISCO, Calif., Sept. 9, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Aclaris Therapeutics International Limited (ATIL), a wholly owned subsidiary of Aclaris Therapeutics, Inc., and Rigel have entered into an exclusive, worldwide license agreement for the development and commercialization of specified Rigel JAK inhibitors for the treatment of alopecia areata and other dermatological conditions. Under the license agreement, ATIL will assume ... 
Download PDFPrinter Friendly Version
09/08/15Rigel Granted Orphan Drug Designation for Fostamatinib in ITP
SOUTH SAN FRANCISCO, Calif., Sept. 8, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor which is currently in Phase 3 clinical studies in patients with chronic immune thrombocytopenic purpura (ITP).  Rigel's Phase 3 program for Fostamatinib in ITP, called FIT, has surpassed the half-way point in enrollment and Rigel expe... 
Download PDFPrinter Friendly Version
08/04/15Rigel Announces Second Quarter 2015 Financial Results
- Conference Call and Webcast Today at 4:30 PM Eastern Time - SOUTH SAN FRANCISCO, Calif., Aug. 4, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2015. "The Phase 3 clinical studies with fostamatinib in ITP are progressing and we continue to expect results in the middle of 2016," said Raul Rodriguez, president and chief executive officer of Rigel. "We are also focused on the advancement ... 
Download PDFPrinter Friendly Version
07/28/15Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results
SOUTH SAN FRANCISCO, Calif., July 28, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2015 financial results after market close on Tuesday, August 4, 2015.  Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results. Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-293... 
Download PDFPrinter Friendly Version
06/30/15Rigel Welcomes Keith A. Katkin to Board of Directors
SOUTH SAN FRANCISCO, Calif., June 30, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Keith A. Katkin, president and chief executive officer of Avanir Pharmaceuticals, has been appointed to Rigel's board of directors.  Mr. Katkin brings to Rigel's board extensive biopharmaceutical experience in commercial development, business development and operational management.   "Keith's background in directing product launches and his successful leadership of Avani... 
Download PDFPrinter Friendly Version
05/28/15Rigel to Present at Jefferies 2015 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 28, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies 2015 Global Healthcare Conference in New York City on Wednesday, June 3rd at 1:30 p.m. ET. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to ... 
Download PDFPrinter Friendly Version
05/07/15Rigel Announces First Quarter 2015 Financial Results
- Conference Call and Webcast Today at 4:30 PM Eastern Time - SOUTH SAN FRANCISCO, Calif., May 7, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2015. For the first quarter of 2015, Rigel reported a net loss of $18.2 million, or $0.21 per share, compared to a net loss of $22.3 million, or $0.25 per share, in the first quarter of 2014. Weighted average shares outstanding for the first quarters of 2015 a... 
Download PDFPrinter Friendly Version
04/30/15Rigel Announces Conference Call and Webcast to Report First Quarter 2015 Financial Results and Pipeline Update
SOUTH SAN FRANCISCO, Calif., April 30, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2015 financial results after market close on Thursday, May 7, 2015.  Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and provide an update on the Company's clinical programs and pipeline. Participants can access the li... 
Download PDFPrinter Friendly Version
03/03/15Rigel Announces Fourth Quarter and Year End 2014 Financial Results
SOUTH SAN FRANCISCO, Calif., March 3, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, Rigel reported a net loss of $22.3 million, or $0.25 per share, compared to a net loss of $16.9 million, or $0.19 per share, in the fourth quarter of 2013. Weighted average shares outstanding for the fourth quarters of 2014 and 2013 were 87.8 million and 87.4 million, res... 
Download PDFPrinter Friendly Version
02/23/15Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications
SOUTH SAN FRANCISCO, Calif. and NEW YORK, February 23, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability ... 
Download PDFPrinter Friendly Version
01/08/15Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Earns $5.75M Milestone from AstraZeneca for Asthma Program SOUTH SAN FRANCISCO, Jan. 8, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present updated product development plans and a financial update at the upcoming 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15th at 9:00 a.m. PT (see webcast details below).  The presentation will focus o... 
Download PDFPrinter Friendly Version